Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

155.84 +0.67 (+0.43%)
Streaming Delayed Price Updated: 1:21 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
99 100 Next >
7 blue chip stocks to Buy on the Dip: April 2024
Each of these seven blue-chip stocks to buy on the dip offer high-quality at a more-than-reasonable price. 
Via InvestorPlace
Medtech Marvels: 3 Groundbreaking Medical Device Stocks to Watch in 2024
The medical device market is growing fast, and top medical device firms can become takeover targets. Here are three medtech stocks to watch. 
Via InvestorPlace
Johnson & Johnson Stocks Elliott Wave Technical Analysis
Looking for support as we touched 0.618 Z vs. X. If we find resistance on Medium Level at 150 then we can expected further downside. 
Via Talk Markets
The Top 7 Dividend Stocks to Buy in 2024 to Build Lasting Wealth
Discover the top dividend stocks for prolonged wealth in 2024 in pharmaceuticals, integrated telecommunications, drug retail, and tobacco. 
Via InvestorPlace
These Are the 10 High-Profile Stocks U.S. Politicians Have Gravitated to Most Over the Last 3 Years
These stocks kept members of Congress especially busy. 
Via The Motley Fool
Unpacking the Latest Options Trading Trends in Johnson & Johnson
Via Benzinga
Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever
Buying great stocks when they're on sale is a lucrative long-term strategy. 
Via The Motley Fool
Warning! These 3 Blue-Chip Stocks Will Have You Seeing Red
These stocks are underwater right now and likely to remain so as the companies behind them manage serious problems. 
Via InvestorPlace
No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win
The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza. 
Via Investor's Business Daily
Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)
From Johnson & Johnson
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Macatawa Bank Corporation (Nasdaq - MCBC), Shockwave Medical, Inc. (Nasdaq – SWAV), Apartment Income REIT Corp. (NYSE - AIRC), Model N, Inc. (NYSE – MODN)
From Brodsky & Smith LLC
Via GlobeNewswire
3 Dividend Stocks to Buy Now for Lifelong Income
Here are three dividend stocks to buy now offering stability, growth, and lifelong income in the pharmaceutical and tobacco industries. 
Via InvestorPlace
5 Crash-Proof Stocks to Buy Immediately
We may not be headed to a full-blown crisis, but savvy investors should protect their portfolios now with these crash-proof stocks. 
Via InvestorPlace
3 Dividend Kings Down 11% You’ll Regret Not Buying on the Dip
These dividend stocks have proved time and again why they're the cream of the crop and will rise to the top once more. 
Via InvestorPlace
MarketBeat Week in Review – 4/15 - 4/19
The markets continued to move lower ahead of a big earnings week as analysts adjust valuations on the outlook for interest rates and geopolitical concerns 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Investing for the Long-Term: 3 Stocks With Proven Track Records
As uncertainty in the global economy and geopolitical climate abounds, investors should focus on stocks with proven track records. 
Via InvestorPlace
Topics Economy
Exposures Economy
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game. 
Via InvestorPlace
Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review
The Nasdaq and S&P 500 tumbled below their 50-day lines. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
Discover the impact of Brexit on UK drug shortages. Insights from a recent Nuffield Trust study reveal a doubling in shortages since 2020. Learn about challenges in medicine supplies, regulatory... 
Via Benzinga
Topics Brexit
Exposures Brexit
Johnson & Johnson Children's Cough Syrup Contaminated In Some Batches - WHO Poised to Issue Global Alert
WHO alerts the global community about tainted children's cough syrup by Johnson & Johnson. Elevated toxin levels detected in Benylin syrup prompt recalls across Africa. Investigation is underway. 
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
Via Benzinga
Exposures Product Safety
Top Stock Reports For Nvidia, Alphabet And Johnson & Johnson
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Alphabet Inc. (GOOGL) and Johnson & Johnson (JNJ). 
Via Talk Markets
Recession-Proof Riches: 3 Stocks That Thrive in Any Economy
Discover recession-proof stocks that thrive amid economic uncertainty, offering stability and consistent growth. 
Via InvestorPlace
Want to Double Your Tax Refund in 2024? 7 Stocks to Buy Now.
Investors wondering which tax refund stocks to invest in should consider these names, each of which is a capital compounder. 
Via InvestorPlace
Johnson & Johnson Shares Hold Steady After Q1 Earnings, Analysts Optimistic About Future
Johnson & Johnson reports first-quarter earnings, with adjusted EPS up 12.4% and sales up 2.3%. Analysts optimistic about stock's future, highlighting potential growth from new drug approvals. JNJ aims... 
Via Benzinga
Johnson & Johnson Analysts Cut Their Forecasts After Q1 Results
Johnson & Johnson (NYSE: JNJ) reported better-than-expected first-quarter earnings on Tuesday. 
Via Benzinga
Invest Like a Hawk: 7 Stocks to Own If the Fed Stays Tough
Although monetary policy seemed to be moving in a dovish direction, a pivot may warrant a look at stocks for Fed hikes. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Put $10,000 in These 3 Dividend Stocks by 2025
In market uncertainty, dividend stocks come to the rescue. Rebalance your portfolio with these three dividend stocks and enjoy steady income. 
Via InvestorPlace
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
Johnson & Johnson's Q1 2024 earnings offer a mixed picture of resilience amidst economic headwinds and provide insight into the broader medtech sector's health. 
Via MarketBeat
Topics Economy
Exposures COVID-19 Supply Chain
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.